Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam, Cefepime, or Meropenem-Reference-Cited by-同舟云学术

Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam, Cefepime, or Meropenem

Published:2019-05 Issue:5 Volume:63 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Blevins Adam M.¹,Lashinsky Jennifer N.²,McCammon Craig²,Kollef Marin³,Micek Scott²⁴,Juang Paul²⁴

Affiliation:

1. Department of Pharmacy, The University of Kansas Health System, Kansas City, Kansas, USA

2. Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, Missouri, USA

3. Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, St. Louis, Missouri, USA

4. Department of Pharmacy Practice, St. Louis College of Pharmacy, St. Louis, Missouri, USA

Abstract

Critically ill patients are frequently treated with empirical antibiotic therapy, including vancomycin and β-lactams. Recent evidence suggests an increased risk of acute kidney injury (AKI) in patients who received a combination of vancomycin and piperacillin-tazobactam (VPT) compared with patients who received vancomycin alone or vancomycin in combination with cefepime (VC) or meropenem (VM), but most studies were conducted predominately in the non-critically ill population.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02658-18

Reference45 articles.

1. Surviving Sepsis Campaign

2. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society

3. Acute Kidney Injury, Mortality, Length of Stay, and Costs in Hospitalized Patients

4. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study

5. Effects of non-severe acute kidney injury on clinical outcomes in critically ill patients

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The critical care literature 2023;The American Journal of Emergency Medicine;2024-11

2. Acute Kidney Injury in a Febrile Neutropenic Post-chemotherapy Patient Following Combination Antibiotic Therapy- a Case Report;2024-08-07

3. Effect modification of dosing strategy (AUC or trough) on AKI associated with vancomycin in combination with piperacillin/tazobactam or cefepime and meropenem;Antimicrobial Agents and Chemotherapy;2024-05-02

4. Epidemiology of Vancomycin in Combination With Piperacillin/Tazobactam-Associated Acute Kidney Injury in Children: A Systematic Review and Meta-analysis;Annals of Pharmacotherapy;2024-01-27

5. Association between piperacillin/tazobactam use and acute kidney injury in critically ill patients: a retrospective multicentre cohort study;Journal of Antimicrobial Chemotherapy;2024-01-22